These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 715242)

  • 21. [Pindolol in arterial hypertension. Multicentric study with 15 mg. of Viskene (pindolol) in a single daily dose].
    Abetel G; Christeler P; Henry M; Karly M; Knobel P; Magnenat G; Morandi D; de Senarclens B; Terrier P
    Rev Med Suisse Romande; 1977 Aug; 97(8):367-72. PubMed ID: 929024
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of arterial hypertension by pindolol].
    Guédon J; Lucsko M; Chaignon M
    Nouv Presse Med; 1976 Feb; 5(8):511-2. PubMed ID: 817263
    [No Abstract]   [Full Text] [Related]  

  • 23. [The effect of visken and hypothiazide on the indices of the central and renal hemodynamics in patients with atherosclerotic hypertension].
    Shishkina OS
    Vrach Delo; 1990 Apr; (4):41-3. PubMed ID: 2275163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pindolol in the treatment of arterial hypertension].
    Strozzi C; Cocco G
    Minerva Med; 1978 Jan; 69(4):247-56. PubMed ID: 342988
    [No Abstract]   [Full Text] [Related]  

  • 25. [Elevation of serum creatine phosphokinase during pindolol treatment (author's transl)].
    Imataka K; Seki A; Takahashi N; Fujii J; Ohuchi Y; Kuwako K; Umeda T; Machii K; Hasegawa T; Ozoe A
    Nihon Naika Gakkai Zasshi; 1981 Apr; 70(4):580-5. PubMed ID: 7288241
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacokinetics of pindolol in a group of elderly hypertensive patients (author's transl)].
    Salathé B; Kerle FH
    Aktuelle Gerontol; 1980 Oct; 10(10):443-7. PubMed ID: 6110350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relation between the effect of sectral and visken in stage 2 hypertension patients and the sensitivity of the nervous system].
    Lil'in ET; Vavilova TA; Mar'in MI
    Klin Med (Mosk); 1983 Sep; 61(9):85-9. PubMed ID: 6139506
    [No Abstract]   [Full Text] [Related]  

  • 28. [Bopindolol in the treatment of mild and moderate arterial hypertension].
    Monaci R; Morganti G; Cecchin A; Morandini M
    Minerva Cardioangiol; 1988 Oct; 36(10):495-7. PubMed ID: 2906412
    [No Abstract]   [Full Text] [Related]  

  • 29. [Use of the adrenergic beta receptor blockader, visken, (prindolol) in arterial hypertension].
    Savenkov PM; Doshitsin VL; Grudtsyn GV
    Kardiologiia; 1977 Oct; 17(10):62-6. PubMed ID: 599799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of the drug combination of hypothiazide+Visken+Halidor in hypertension.
    Molnár K; Kömíves S; Kalmár J; Gerzon J
    Ther Hung; 1978; 26(3):132-4. PubMed ID: 725817
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pressor reaction of hypertonic subjects to physical exercise of submaximal intensity under the influence of beta-adrenergic block (Pindolol) (author's transl)].
    Chrástek J; Boudová L; Kavánková M; Benes K; Krízek V; Matousek O
    Sb Lek; 1973 Oct; 75(10):301-11. PubMed ID: 4759769
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative study with Tobanum and Visken in hypertensive patients.
    Torma Z; Grubic V; Unyi G
    Ther Hung; 1983; 31(3):129-35. PubMed ID: 6152822
    [No Abstract]   [Full Text] [Related]  

  • 33. [The practice of hypertensive therapy using a beta receptor blocker. A multicentric study using 15 mg Visken].
    Rosenthal J; Kaiser H; Hammerschmidt D; Welzel D
    Med Welt; 1977 Dec; 28(48):1969-74. PubMed ID: 600069
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of pindolol (Visken) on plasma and blood volume in men with primary arterial hypertension].
    Wyrzykowski B; Suchecka-Rachoń K
    Pol Tyg Lek; 1985 Sep; 40(38):1083-6. PubMed ID: 3906604
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of essential hypertension with pindolol].
    Kocemba J; Kawecka-Jaszcz K; Sniezek M; Starzycka M; Augustyński W
    Kardiol Pol; 1978; 21(3):201-8. PubMed ID: 691928
    [No Abstract]   [Full Text] [Related]  

  • 36. [The efficiency of coronary therapy with Visken (pindolol). A combined clinical and experimental analysis (author's transl)].
    Delius L; Lübke KO
    Med Klin; 1974 Jun; 69(25):1117-23. PubMed ID: 4602393
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of the beta-receptor blocking agent visken on blood pressure of hypertensive patients, on plasma renin activity and electrolytes.
    Sonkodi S; Pap A; Varró V
    Ther Hung; 1976; 24(2):60-2. PubMed ID: 982340
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experience in using visken in ischemic heart disease and arterial hypertension].
    Komarov FI; Kun IS; Markova VM; Mytareva IL; Ostrovskaia VI
    Sov Med; 1977 Jan; (1):53-5. PubMed ID: 847522
    [No Abstract]   [Full Text] [Related]  

  • 39. Atenolol in hypertension: follow-up of patients crossed over to this agent from propranolol, pindolol or metoprolol.
    Frewin DB; Penhall RK; Leonello PP; Clapp RJ
    N Z Med J; 1980 Nov; 92(672):389-90. PubMed ID: 6937768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twice-daily pindolol and alprenolol in essential hypertension of moderate severity.
    Hartikainen M; Heikkilä J
    Ann Clin Res; 1976 Apr; 8(2):85-92. PubMed ID: 779590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.